Representative image delineating the plausible anti-hypertensive effect of CM. At the molecular level, the renin-angiotensin system (RAS) is at the center of the regulation of hypertension. Angiotensin II (Ang II), an important effector RAS hormone, has been implicated in regulating the physiological effects of the regulation of blood pressure and is associated with the pathophysiology of hypertension. Basically, Ang II is derived from Ang I through the activity of Angiotensin Converting Enzyme (ACE). ACE, or kininase II, also plays a key role in the kallikrein-kinin system by cleaving bradykinin to inactive peptides; which, in turn, also affect hypertensive responses (
). Molecular signaling through AT
R is envisaged to mediate aldosterone secretion, ADH secretion, and the arterial vasoconstriction, which ultimately leads to hypertensive response (
). A detailed overview of the molecular signaling mediated by Ang II-AT1R is delineated (
). Interestingly, CM and its constituents have been reported to inhibit ACE.
Ang II has been shown to mediate downstream signaling through the action of G protein- and non-G protein-related signaling mediators
[62][66][96,98]. However, Ang II also mediates its functions via various mitogen-activated protein kinases, receptor tyrosine kinases and non-receptor tyrosine kinases
[66][98]. In addition, Ang II-AT
1R-mediated NAD(P)H oxidase activation, which has been widely implicated in vascular inflammatory and fibrotic responses, has been studied in detail. These signaling pathways regulate normal cellular function and/or disease conditions. A detailed overview of the signal transduction pathways related to Ang II-mediated hypertensive responses is delineated in
Figure 3. The plausible target for CM and its constituents has also been highlighted (
Figure 3).
Interestingly, the anti-hypertensive potential of CM proteins, PHs and/or bioactive peptides is an important emerging area with promising prospects. It is important to understand how these CM bioactive molecules influence the cellular system at the molecular, cellular, and organelle levels. Further, it is anticipated that the underlying events do not function in isolation but rather influence each other either directly or indirectly, and ultimately affect the underlying responses. Thus, it is equally imperative to understand how these CM bioactive molecules influence these dynamically intertwined responses.、
2.3. Non-Nutritional Components (CM Exosomes)
While the nutritional components of CM have long been recognized and studied in depth, research on the non-nutritional components of CM has recently accelerated
[1][3][1,3]. Since antiquity, milk, especially CM, has been shown to possess various desirable pharmacological properties
[1][15][75][76][1,15,52,110]. As already mentioned, accumulating evidence has shown that CM bioactive molecules possess various beneficial characteristics, including anti-oxidant, anti-microbial, anti-radical, anti-cancer, anti-hypertension, anti-diabetic, anti-inflammatory, anti-allergic, anti-autism, immunomodulatory effects, etc.
[7][15][24][77][7,15,24,63]. Recent studies have highlighted that these properties can be attributed to the presence of EVs, especially exosomes
[1][3][1,3]. Milk exosomes have attracted much attention, primarily due to their intrinsic beneficial properties but also because they can serve as nanodrug delivery platforms for therapeutic agents and molecular entities. Further fabrication of exosomes with targeting moieties would allow targeted delivery of drugs/molecular entities to the desired sites.
Exosomes are naturally occurring, nano-sized (20–100 nm) EVs that are released from almost every cell type
[78][79][123,124]. They are found throughout the body in the extracellular environment and biofluids, including cerebrospinal fluid, serum, saliva, urine, and milk
[78][79][80][81][82][123,124,125,126,127]. They are mechanistically and functionally diverse from their cellular counterparts and are more heterogeneous, depending on their origin. They are lipid bilayer assemblies containing membrane-bound and internal proteins and a wide range of nucleic acid moieties
[79][124]. It is thought that cellular communication by exosomes occurs through their ability to shuttle cargoes of proteins, circulating DNA, noncoding RNAs, lipid moieties, and metabolites into their surrounding milieu
[79][83][84][85][124,128,129,130]. For example, it has been shown that milk exosomes shuttle genetic material from parents to offspring, thereby playing a role in the regulation of the infant’s development
[84][129].
3. Pharmacological Properties of CM Exosomes
Evidence has shown that exosomes derived from human milk, BM, and CM exhibit antitumor activities
[86][87][35,131]; however, reports on their anti-diabetic and anti-hypertensive potential are scarce.
3.1. Molecular Intricacies of Their Anti-Cancer Potential
There are many reports on the anti-cancer potential of milk-derived exosomes from bovine sources, and research on CM exosomes is still in its infancy. To the best of
our
esearchers' knowledge, Badawy et al. were the first to evaluate the potential effects of CM and its exosomes against breast cancer; they evaluated their chemotherapeutic potential and provided evidence for the underlying mechanism of action
[1]. They suggested that the anti-cancer effect of CM exosomes was mediated through the regulation of apoptosis and suppression of angiogenesis, metastasis, and inflammatory responses and that these effects were attributable to miRNA constituents of the exosomes
[1]. CM exosomes have also been reported to mitigate oxidative stress and immuno-toxic responses induced by the chemotherapeutic drug cyclophosphamide in an albino rat model
[3]. Recently, El-Magd have envisaged the apoptotic, anti-inflammatory, and anti-angiogenesis properties of CM exosomes from colostrum against HepaRG cells
[88][80].
3.2. CM Exosomes as a Natural Biogenic Nano-Delivery Platform for Therapeutics
Milk-derived exosomes have garnered much interest, not only for their intrinsic beneficial properties, but also for their ability to serve as biomimetic nanodrug delivery platforms. The use of milk exosomes as a delivery vehicle for therapeutic drugs and/or siRNA, and the development of exosome-based targeted delivery platforms, constitute an emerging and exciting field.
Gupta et al. were the first to examine the potential of bovine exosomes as a biogenic nano-delivery platform for chemotherapeutic drugs, such as paclitaxel, curcumin, anthocyanidins, celastrol, and siRNA
[89][90][91][92][93][132,133,134,135,136]. Yassin et al. described a method for isolating CM exosomes using differential ultracentrifugation and provided an in-depth characterization of CM exosomes
[94][66]. They showed that CM exosomes have a truncated 35-kDa protein of the TSG101 marker (compared with the mammalian 43-kDa protein) and an average size of approximately 30 nm. Additionally, using phospholipidomic analysis, PC was found to be the most abundant phospholipid. A detailed analysis of EVs isolated from CM using liquid chromatography with tandem mass spectrometry revealed a variety of protein signatures associated with small EVs, including ADAM10, TSG101, CD3, CD63, CD81, HSP70, and HSP90, which suggests that CM EVs are rich in exosomal proteins. While CM exosomes offer exciting research potential, to leverage their full potential, further standardization and optimization of isolation protocols and improved quality control are important aspects that must not be overlooked. It is equally important to assess the individual components of exosomes responsible for the underlying effects, in parallel with the assessment of their potential toxicity issues.